ADMA Biologics Inc $ADMA Shares Purchased by Advantage Alpha Capital Partners LP

Key Points

• Advantage Alpha Capital Partners LP increased its stake in ADMA Biologics by 53.3%, owning 106,075 shares valued at approximately $2.1 million at the end of the most recent quarter.
• ADMA Biologics reported earnings of $0.15 per share for the latest quarter, slightly exceeding analysts' expectations of $0.14, with a revenue increase of 13.8% compared to the same period last year.
• ADMA's stock has a consensus rating of "Buy" with a target price of $27.67, and it is currently trading around $17.10, reflecting a downward movement of 1.2% in recent sessions.

Advantage Alpha Capital Partners LP increased its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA - Free Report) by 53.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,075 shares of the biotechnology company's stock after purchasing an additional 36,893 shares during the quarter. Advantage Alpha Capital Partners LP's holdings in ADMA Biologics were worth $2,105,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ADMA. Envestnet Asset Management Inc. grew its stake in ADMA Biologics by 68.0% during the 4th quarter. Envestnet Asset Management Inc. now owns 60,004 shares of the biotechnology company's stock worth $1,029,000 after purchasing an additional 24,293 shares in the last quarter. Mariner LLC purchased a new stake in ADMA Biologics during the 4th quarter worth about $573,000. Jump Financial LLC purchased a new stake in ADMA Biologics during the 4th quarter worth about $403,000. Dimensional Fund Advisors LP lifted its holdings in ADMA Biologics by 16.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock worth $80,065,000 after buying an additional 643,661 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in shares of ADMA Biologics by 4.7% in the 4th quarter. MetLife Investment Management LLC now owns 136,212 shares of the biotechnology company's stock valued at $2,336,000 after purchasing an additional 6,060 shares during the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ADMA Biologics

In other news, Director Steve Elms sold 194,749 shares of the firm's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the sale, the director owned 87,330 shares in the company, valued at $1,767,559.20. This trade represents a 69.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jerrold B. Grossman sold 10,000 shares of the firm's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $21.31, for a total value of $213,100.00. Following the sale, the director owned 478,194 shares in the company, valued at $10,190,314.14. This trade represents a 2.05% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 455,621 shares of company stock worth $9,461,633 over the last quarter. 3.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

ADMA has been the subject of a number of research analyst reports. Wall Street Zen cut ADMA Biologics from a "hold" rating to a "sell" rating in a research report on Friday, May 9th. Raymond James Financial upped their target price on ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a research report on Thursday, May 8th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $27.67.

ADMA Biologics Price Performance

ADMA Biologics stock traded up $0.21 during mid-day trading on Wednesday, hitting $17.31. 1,017,713 shares of the company were exchanged, compared to its average volume of 3,099,571. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.33 and a quick ratio of 2.78. The business's 50 day simple moving average is $17.81 and its two-hundred day simple moving average is $18.89. The company has a market capitalization of $4.13 billion, a P/E ratio of 20.13 and a beta of 0.38. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.01. The company had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.ADMA Biologics's revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.13 earnings per share. Analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.